Article Text

Download PDFPDF
Serous Ovarian Cancer Signaling Pathways
  1. Ioannis C. Kotsopoulos, MD*,
  2. Alexios Papanikolaou, MD, PhD,
  3. Alexandros F. Lambropoulos, PhD,
  4. Konstantinos T. Papazisis, MD, PhD,
  5. Dimitrios Tsolakidis, MD, PhD,
  6. Panagiota Touplikioti, PhD§ and
  7. Basil C. Tarlatzis, MD, PhD
  1. *Obstetrics & Gynecology Department, Medical School, University of Patras, Rion; and
  2. 1st Obstetrics & Gynecology Department, Medical School, “Aristotle” University of Thessaloniki;
  3. Medical Oncology Department, “Euromedica” General Clinic; and
  4. §Cytology Department, “Theagenio” Cancer Hospital, Thessaloniki, Greece.
  1. Address correspondence and reprint requests to Ioannis C. Kotsopoulos, MD, Obstetrics & Gynecology Department, Medical School, University of Patras, Rion, Greece; and Tyrnovou 14, 53100, Florina, Greece. E-mail: ykotsopoulos{at}yahoo.gr.

Abstract

Abstract Ovarian cancer is the most lethal malignancy of the female genital tract, mainly due to the failure of early diagnosis and the limitations posed by the conventional chemotherapies. Current research has focused in the study of cascades of various cellular molecular reactions, known as signaling pathways. In this review article, authors try to describe the current knowledge regarding the signaling pathways that influence multiple cellular processes in serous ovarian cancer and especially the pathogenesis. Thorough understanding of the precise role of these pathways can lead to the development of new and more effective targeted therapies as well as novel biomarkers in ovarian cancer.

  • Serous ovarian cancer
  • Signaling pathways
  • Pathogenesis

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • No funding was received for this study.

  • The authors declare no conflicts of interest.